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Background: The role of extended pulmonary resection for lung 
metastases is still unclear, and little information is available in the 
literature. This study was performed to analyze the outcomes and 
prognostic factors of patients who underwent extended resections for 
pulmonary metastases.
Methods: From 1998 to 2013, 1027 patients underwent lung metas-
tasectomy procedures. Twenty-nine patients had extended pulmonary 
resections: three resections of the chest wall, one azygos, one dia-
phragm, four vascular resections/reconstructions, six sleeve resec-
tions, and 14 pneumonectomies.
Results: Extended resection was performed for metastatic dis-
ease mainly from epithelial (62.1%) and sarcomatous (20.7%) 
tumors. Complete resection was obtained in all patients. Thirty-
day operative morbidity and mortality rates were 38% (11 of 29) 
and 0%, respectively. Only one patient had a major complication 
due to a bronchopleural fistula. Mean hospital stay was 6.3 days. 
After a median follow-up of 27 months, 16 patients (55%) had 
died. At univariate analysis, survival was determined by primary 
tumor histology (p = 0.03); the number of metastases, nodal sta-
tus, disease-free interval or extension of surgery (pneumonec-
tomy vs. lobar resection) were not related to survival probably due 
to the low number of patients. Overall survival after a complete 
extended metastasectomy was 66% at 2 years, 42% at 5 years, and 
36% at 10 years.
Conclusions: Extended resections performed during pulmonary 
metastasectomies are associated with low mortality and morbid-
ity rates and an acceptable long-term survival when performed in 
selected patients susceptible to complete resection.
Key Words: Extended surgery, Lung metastasectomy, Morbidity and 
mortality, Outcome.
(J Thorac Oncol. 2015;10: 924–929)
In the past, pulmonary metastases (PM) were considered fatal in less than 2 years,1,2 and had no indication for sur-
gical treatment. Since 1927, when George Divis described 
the first intentional lung metastasectomy, many case reports 
have shown that surgical resection of lung metastases could 
improve survival in selected patients.3,4
Whereas pneumonectomy and lobectomy were the pre-
dominant resections performed for PM until the late 1940s, 
advances in imaging technology in the early 1980s led to the 
detection of smaller and asymptomatic nodules in the follow-
up of cancer patients. This allowed the more conservative lung-
sparing resection to become the standard surgical procedure 
for those patients.5–12 In 1947, Alexander and Haight7 reported 
42% of pneumonectomies and 50% of lobectomies for lung 
metastases, compared with rates of 4% and 6% reported in 
1984 by Mountain et al. and the Memorial Sloan-Kettering 
experience, respectively.11,12
Even if the recent surgical trend for lung metasta-
sectomy is “lung sparing” surgical resection, major resec-
tions could still be reserved for highly selected patients. As 
already demonstrated in the literature, the completeness of 
surgery after pulmonary metastasectomy is the most impor-
tant prognostic factor in terms of survival.13 Because surgery 
should be offered with a prospect of cure, it seems obvious to 
consider extended resection a therapeutic option to achieve 
long-term survival.
In 1993, Putnam and et al.14 were the first to establish 
that resections of multiple PM or PM involving more than 
lung parenchyma were technically similar to resections for 
locally advanced non–small-cell lung cancer. They defined 
extended resection as pneumonectomy or pulmonary resec-
tion with en bloc resection of the chest wall or other major 
structures (diaphragm, pericardium, superior vena cava).
Unfortunately, the role of extended pulmonary resec-
tion for lung metastases is still unclear, and little information is 
available in the literature. This study was performed to analyze 
the outcomes and feasibility of extended resections for PM.
PATIENTS AND METHODS
From 1998 to 2013, 1027 consecutive patients at the 
European Institute of Oncology (IEO, Milan, Italy) underwent 
lung metastasectomy procedures. Patients’ individual consent 
for the use of their clinical data for research purposes was 
obtained before intervention. Twenty-nine patients (2.8%) had 
extended pulmonary resections defined as pneumonectomy or 
pulmonary resection with en bloc resection of the chest wall 
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or other major structures (diaphragm, pericardium, superior 
vena cava).
All patients included in the analysis had a controlled or 
controllable primary tumor, and no extrapulmonary metasta-
ses. Suspected pulmonary metastatic lesions were evaluated 
during pretreatment and tumor staging or during regular fol-
low-up after resection of primary tumors. All patients were 
studied with contrast-enhanced total body computed tomogra-
phy (CT) scan; positron emission tomography/CT (PET/CT) 
with fluorodeoxyglucose has been routinely used since 2001, 
and performed in 22 patients showing no evidence of extra 
thoracic metastases. Five patients underwent preoperatory 
CT-guided fine needle aspiration biopsy with a positive result 
in four cases, negative in one. Bronchoscopy was performed 
in seven patients with lesions situated near the tracheobron-
chial tree, and in six cases it was diagnostic. All 19 patients 
who did not have a preoperative diagnosis underwent an intra-
operative frozen section of the tumor to confirm the diagnosis 
of metastasis and the planned surgery; we usually performed 
an intraoperative biopsy of the tumor using a trucut procedure 
to reduce possible intracavity dissemination.
Thoracic surgeons, radiotherapists, and oncologists con-
firmed patients’ resectability during a multidisciplinary meet-
ing based on the following selection criteria: primary tumor 
controlled, disease-free interval (DFI), absence of extra tho-
racic metastases highlighted by modern staging system, such 
as CT scan and PET scan, technical feasibility of the pulmo-
nary resection, adequate preoperative cardiac and respiratory 
function evaluated with forced expiratory volume in the 1st 
second, diffusing capacity of the lung for carbon monoxide, 
and perfusion lung scan in case of pneumonectomy. Besides 
these selection criteria, every patient was evaluated case by 
case analyzing the previous medical treatments performed, 
and considering the surgery as the best therapeutic option for 
these patients.
All lung nodules were identified visually or by palpa-
tion depending to the site of resection and histopathologically 
analyzed/confirmed during surgery. Extended resection was 
performed by means of open surgery in all cases. Lymph node 
dissection or sampling was performed in 25 cases.
Based on the oncologist’s evaluation, 18 patients (62.1%) 
received chemotherapy before surgical resection of the lung 
nodules, and five patients (17.2%) received it afterwards.
DFI was defined as the time between treatment of the 
primary tumor and diagnosis of metastases.
Operative mortality was defined as death occurring 
within 30 days of extended resection, and all deaths beyond 
30 days but during the same hospital stay. Postoperative com-
plications were classified as minor or major.15,16
Statistical Methods
Overall survival was defined from the date of metasta-
sectomy to the date of last contact or death. Overall survival 
curves were plotted using the Kaplan–Meier method and 
the log-rank test was used to assess differences in survival 
between groups. Univariate and multivariate Cox proportional 
hazard regression was used to assess the association between 
clinical characteristics and overall survival rates. Analyses 
were performed with SAS software version 8.2 (Cary, NC). 
All p values were two-sided.
RESULTS
Ten were men and 19 were women. Mean age was 56 
years (range 18–81 years). Primary tumors were classified in 
four histological categories: epithelial, sarcoma, melanoma, 
and germ cell tumors. Eighteen patients (62.1%) developed 
metastases from epithelial tumor, six (20.7%) from sarcoma, 
four (13.8%) from melanoma, and one (3.4%) from germ cell 
tumor. Besides the histology of the primary tumor according 
to the completeness of resection (epithelial, sarcoma, mela-
noma, and germ cell tumors), we specified in detail the ana-
tomical site of the epithelial tumors in Table 1.
Complete resection was obtained in all patients.
DFI was 0 to 12 months in three patients (10.3%), 12 to 
36 months in eight patients (27.6%), and 36 months or more 
in 18 patients (62.1%). Nineteen patients had a single lung 
metastasis and 10 had multiple lesions.
Fourteen patients underwent pneumonectomies, 
whereas lobectomies and sublobar resections were performed 
on 11 and four patients, respectively. Pulmonary resection was 
associated with chest wall resection in three patients, pulmo-
nary artery resection in three (two resection and reconstruction 
and one vascular sleeve), bronchial sleeve resections in six, 
azygos vein resection in one, diaphragm resection in one, and 
pericardium resection, and reconstruction in one. Pulmonary 
artery and pericardium were reconstructed with bovine peri-
cardium patch, and chest wall with methacrylate prosthesis. 
Diaphragm was resected with no need of reconstruction.
Data on the indications for extended resection, such as 
histological primary tumor types, number of PM, preopera-
tive respiratory function, such as forced expiratory volume in 
the 1st second and diffusing capacity of the lung for carbon 
monoxide, presence or absence of nodal metastases, surgical 
approach, DFI, and relapses are described in detail in Table 1.
Only one patient underwent pneumonectomy had a 
major complication due to bronchopleural fistula treated by 
thoracostomy after 30 days. Minor complications occurred 
in 10 patients (34.4%): atrial fibrillation was the most fre-
quent complication (6 of 10), followed by anemia and atel-
ectasis necessitating aspiration of bronchial secretions. More 
details regarding postoperative complication are presented 
in Table 2.
Median intensive care unit stay was 1.3 days (range 1–3 
days) and the median length of total hospital stay was 6.3 days 
(range 3–10 days). No intraoperative mortality was observed. 
Thirty-day operative morbidity and mortality rates were 38% 
(11 of 29) and 0%, respectively.
Postoperative treatments, such as chemotherapy or 
radiotherapy were administered to seven patients (24.1%) 
based on multidisciplinary evaluation. Seventeen patients had 
recurrent pulmonary disease, and subsequent metastasectomy 
was performed on four patients: in three patients, metastasec-
tomy was performed contra laterally, and one patient had a 
redo-metastasectomy (on the same side). Seven patients out of 
15 patients who received en bloc resection had systemic recur-
rence whereas none had locoregional recurrence.
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After a median follow-up of 27 months (range <1–186 
months), 14 patients (48%) had died, and 13 patients are alive 
without disease. Overall survival after complete extended 
metastasectomy was 66% at 2 years, 42% at 5 years, and 36% 
at 10 years (Fig. 1).
Survival was determined by primary tumor histology 
(p = 0.02), and not by the number of metastases, nodal status, 
DFI, or extension of surgery (pneumonectomy versus lobar 
resection; Figs. 2 and 3). However, it was evident from the curve 
trend (Fig. 3) that patients who had a pneumonectomy had a 
worse survival compared with patients who had a lobar extended 
resection (27% and 47% at 10 years, respectively), with a median 
survival of 35 months and 38 months, respectively.
At univariate analysis, patients with nonepithelial pri-
mary tumor had a threefold risk of dying after metastasectomy 
(HR = 3.07, 95% CI: 1.13–8.36; p = 0.03). The number of 
metastases, nodal status, DFI, or extension of surgery (pneu-
monectomy vs. lobar resection) were instead not related to 
survival probably due to the low number of patients (Table 3).
DISCUSSION
Although the ESTS Pulmonary Metastasectomy 
Working Group demonstrated that wedge resections were the 
most common way (92%) to resect metastases,17 extended 
resection may have an important role in selected patients with 
centrally located lesions or nodules invading major structures 
(diaphragm, pericardium, superior vena cava, or chest wall) 
to obtain a complete resection improving survival. In fact, the 
purpose of pulmonary metastasectomy is to achieve cure or to 
lengthen survival by removing all known remaining cancer. 
TABLE 1.  Clinical and Surgical Characteristics of the 29 
Patients Who Underwent Extended Lung Resection for 
Metastases
N (%)
Sex
  Men 10 (34.5)
  Woman 19 (65.5)
Age
  <50 9 (31.0)
  50–59 10 (34.5)
  60+ 10 (34.5)
Primary tumor
  Epitheliala 18 (62.1)
  Sarcoma 6
  Melanoma 4
  Germ cell tumor 1
Number of metastases
  1 19 (65.5)
  2 4 (13.8)
  3+ 6 (20.7)
Nodal status
  N0 16 (55.2)
  N1 4 (13.8)
  N2 5 (17.2)
  Unknown 4 (13.8)
FEV1 (%)
  <75 3 (10.3)
  75–90 4 (13.8)
  90–100 8 (27.6)
  >100 5 (17.2)
  Unknown 9 (31.0)
DLCO (%)
  <90 6 (20.7)
  90–100 4 (13.8)
  >100 6 (20.7)
  Unknown 13 (44.8)
DFI
  <5 years 20 (69.0)
  >5 years 9 (31.0)
Surgery type
  Lobar resection 15 (51.7)
  Pneumonectomy 14 (48.3)
aEight colorectal carcinoma, three breast cancer, one renal carcinoma, six uterine 
carcinoma.
DFI, disease-free interval calculated as the time between treatment of the primary 
tumour and diagnosis of metastases; FEV1, forced expiratory volume in the 1st second; 
DLCO, diffusing capacity of the lung for carbon monoxide.
TABLE 2:  Postoperative Complications
Complicationa Number of Patients (%)
Minor complication 10 (34.4%)
  Atrial fibrillation 6
  Anemia 5
  Atelectasia 1
Major complication 1 (3.4%)
  Broncho-pleural fistula 1
aEleven patients had at least one complication.
FIGURE 1.  Overall postresection survival.
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Very few literature data are available on extended resection 
for lung metastases.14,18–23 Extended lung metastasectomy was 
often oncologically considered overtreatment, and thus not 
accepted worldwide. In addition, extended resection was usu-
ally related to higher postoperative mortality and morbidity 
rates compared with simple wedge resections because it was 
often performed as a last option in patients with a limited car-
diorespiratory reserve after previous lung surgeries.
In 1993, Putnam et al.14 were the first to describe the fea-
sibility of extended resection for lung metastasis in 28 patients 
showing a 5-year overall survival of 25.4% (19 patients under-
went pneumonectomies and 19 had pulmonary resections 
with en bloc chest wall resections or other mediastinal struc-
ture resections). They demonstrated that pneumonectomy for 
pulmonary metastasis could be performed with an operative 
risk equivalent to pneumonectomy for primary lung cancer 
and with an acceptable postoperative mortality rate of 5.3%.14
A study by Spaggiari et al.18 published in 1998 con-
firmed the feasibility of pneumonectomy for lung metastasis, 
showing a 5-year overall survival of 16.8%, and postoperative 
morbidity and mortality rates of 9.8% and 4.8%, respectively. 
However, they emphasized that the poor outcomes in patients 
with incomplete resection suggested strict selection criteria.
Koong et al. reported that 171 patients out of 5206 
underwent primary or completion pneumonectomy for lung 
metastasis with an operative mortality of 4% and a 5-year sur-
vival rate of 20% following complete resection.18 Extended 
resection established curative benefits and no higher operative 
mortality than a similar resection for primary non–small-cell 
lung cancer, and confirmed the poor results in case of incom-
plete resection with no survivors beyond 2 years and a higher 
operative mortality (19%).19
More recently, Tanju et al.20 analyzed 25 patients 
undergoing extended resection and compared them with 225 
patients who underwent lobar or sublobar resections, conclud-
ing that extended resection for pulmonary metastatic disease 
was justified in terms of postoperative outcomes and long-
term survival (16.3% 5-year survival rate).
In our experience, the 5-year survival rate was 42%, 
higher than that of other literature reports. All our 29 patients 
FIGURE 2.  Overall survival according to clinical characteristics.
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had a complete surgical resection, sufficient pulmonary 
reserve, controlled primary disease, and no evidence of other 
metastatic disease showing the importance of selection criteria 
to improve survival. Our survival rate was surprising consid-
ering both the type of surgery and previous literature data. We 
believe that this survival rate was the result of better patient 
selection because of a small but homogeneous database and 
the use of modern staging systems (CT scan and PET/CT), 
which allowed us to check all patients preoperatively and 
eventually exclude them from surgery if extrathoracic or other 
tumor localizations were found. Patients with nonepithelial 
primary tumors had a threefold risk of dying after metastasec-
tomy both at univariate and multivariate analysis, whereas sur-
vival was not statistically related to the number of metastases, 
nodal status, DFI, or extension of surgery. Our overall postop-
erative morbidity was 38% with only one major complication 
(3.4%), and there was no statistically difference between the 
extension of surgery (pneumonectomy vs. lobectomy/sub-
lobar resection), which was 43% in patients who underwent 
pneumonectomy compared with 33% morbidity in the other 
patients who underwent lobar or sublobar resections.
As already demonstrated in many studies, completeness 
of resection (R0) is strictly related to survival. In our series, 
we could not assess the statistical importance of surgical radi-
cality because complete resection was obtained in all patients. 
All patients underwent preoperative staging with PET/CT and 
total body CT scan; imaging findings were discussed by a 
multidisciplinary team (surgeons, oncologists, and radiothera-
pists) to obtain a correct treatment strategy for each patient. 
Extended resection usually represents the only chance of cure 
for these patients, and selection becomes essential to obtain a 
complete surgical resection, offering them the best possible 
long-term survival rate with the lowest possible morbidity.
This study has some limitations primarily due to the 
small cohort and the retrospective analysis.
Due to the limited number of patients and number of 
events, the univariable statistical analysis to assess the prog-
nostic impact of clinical and pathological aspects has only 
limited power and results, in particular the lack of statistically 
significant associations with some patients characteristics 
such DFI or number of metastases should be interpreted with 
caution. The study also lacks a matched control group who did 
FIGURE 3.  Overall survival according to exten-
sion of resection.
TABLE 3.  Prognostic Factors at Univariate Analysis
Univariate Analysis
HR (95% CI) p Value
Primary tumour
  Epithelial 1.00
  Othera 3.07 (1.13–8.36) 0.03
DFI
  <5 years 1.00
  ≥5 years 0.36 (0.10–1.25) 0.11
Number of metastases
  1 1.00
  2 0.69 (0.15–3.17) 0.64
  3+ 1.96 (0.61–6.35) 0.26
Nodal status
  N0 1.00
  N1 1.78 (0.48–6.59) 0.39
  N2 1.75 (0.47–6.59) 0.41
Surgery type
  Lobar resection 1.00
  Pneumonectomy 1.33 (0.50–3.59) 0.57
HR and 95% CI obtained from Cox proportional hazards regression model. Bold 
values indicate statistical significance.
aSix sarcomas, four melanomas, one germ cell tumor.
DFI, disease-free interval calculated as the time between treatment of the primary 
tumor and diagnosis of metastases; FEV1, forced expiratory volume in the 1st second; 
DLCO, diffusing capacity of the lung for carbon monoxide; HR, hazards ratio; CI, 
confidence intervals.
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not underwent extended resection, but the rarity of this type of 
surgery makes randomized controlled trials difficult to carry 
out. Such trial would be highly desirable to establish the use of 
chemotherapy before surgery and possibly exclude from sur-
gery patients with rapidly evolving metastatic disease.
In conclusion, extended resection could be proposed as 
a treatment for PM in highly selected patients with a pros-
pect of cure, and with low rates of operative morbidity and 
mortality.
REFERENCES
 1. McKenna RJ, McKenna RJ Jr. Patterns of pulmonary metastases. An 
orthopedic hospital experience. In Weiss L, Gilbert HA (Eds.), Pulmonary 
Metastasis. Boston, MA: GK Hall & Co, 1978; 1626–1634.
 2. McCormack PM, Bains MS, Martini N. Surgical management of pulmo-
nary metastases. In Shiu M, Brennan M (Eds.), Surgical Management of 
Soft Tissue Sarcoma. Philadelphia, PA: Lea & Febinger, 1989; 70–77.
 3. Edwards AT. Malignant disease of the lung. J Thorac Surg 1934;4:107–24.
 4. Barney JD, Churchill ED. Adenocarcinoma of the kidney with metastases 
to the lung cured by nephrectomy and lobectomy. J Urol 1939;42: 269–76.
 5. Lilienthal H. Pneumonectomy for sarcoma of the lung in a tuberculous 
patient. J Thorac Surg 1933;2:600–15.
 6. Graham EA, Singer JJ. Successful removal of an entire lung for carci-
noma of the bronchus. JAMA 1933;101:1371–74.
 7. Alexander J, Haight C. Pulmonary resection for solitary metastatic sarco-
mas and carcinomas. Surg Gynecol Obstet 1947;85:129–146.
 8. Seiler HH, Clagett OT, McDonald JR. Pulmonary resection for metastatic 
malignant lesions. J Thorac Surg 1950;19:655–679.
 9. Gliedman ML, Horowitz S, Lewis FJ. Lung resection for metastatic can-
cer; 29 cases from the University of Minnesota and a collected review of 
264 cases. Surgery 1957;42:521–532.
 10. Thomford NR, Woolner LB, Clagett OT. The surgical treatment of meta-
static tumors in the lungs. J Thorac Cardiovasc Surg 1965;49:357–363.
 11. McCormack PM, Bains MS, Beattie EJ Jr, Martini N. Pulmonary resec-
tion in metastatic carcinoma. Chest 1978;73:163–166.
 12. Mountain CF, McMurtrey MJ, Hermes KE. Surgery for pulmonary 
metastasis: A 20-year experience. Ann Thorac Surg 1984;38:323–330.
 13. Pastorino U, Buyse M, Friedel G, et al.; International Registry of Lung 
Metastases. Long-term results of lung metastasectomy: Prognostic analy-
ses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113:37–49.
 14. Putnam JB Jr, Suell DM, Natarajan G, Roth JA. Extended resec-
tion of pulmonary metastases: Is the risk justified? Ann Thorac Surg 
1993;55:1440–1446.
 15. Deslauriers J, Ginsberg RJ, Dubois P, Beaulieu M, Goldberg M, Piraux M. 
Current operative morbidity associated with elective surgical resection 
for lung cancer. Can J Surg 1989;32:335–339.
 16. Alloubi I, Jougon J, Delcambre F, Baste JM, Velly JF. Early complica-
tions after pneumonectomy: Retrospective study of 168 patients. Interact 
Cardiovasc Thorac Surg 2010;11:162–165.
 17. Internullo E, Cassivi SD, Van Raemdonck D, Friedel G, Treasure T; ESTS 
Pulmonary Metastasectomy Working Group. Pulmonary metastasec-
tomy: A survey of current practice amongst members of the European 
Society of Thoracic Surgeons. J Thorac Oncol 2008;3:1257–1266.
 18. Spaggiari L, Grunenwald DH, Girard P, Solli P, Le Chevalier T. 
Pneumonectomy for lung metastases: indications, risks, and outcome. 
Ann Thorac Surg 1998;66:1930–1933.
 19. Koong HN, Pastorino U, Ginsberg RJ. Is there a role for pneumonectomy 
in pulmonary metastases? International Registry of Lung Metastases. 
Ann Thorac Surg 1999;68:2039–2043.
 20. Tanju S, Ziyade S, Erus S, Bayrak Y, Toker A, Dilege S. Extended resection: Is 
it feasible for pulmonary metastases? Ann Surg Oncol 2010;17:1912–1916.
 21. Spaggiari L, Grunenwald D, Girard P, Baldeyrou P. Completion right 
lower lobectomy for recurrence after left pneumonectomy for metastases. 
Eur J Cardiothorac Surg 1997;12:798–800.
 22. Grunenwald D, Spaggiari L, Girard P, Baldeyrou P, Filaire M, Dennewald 
G. Completion pneumonectomy for lung metastases: Is it justified? Eur J 
Cardiothorac Surg 1997;12:694–697.
 23. Grunenwald D, Spaggiari L, Girard P, et al. Lung resection for recurrence 
after pneumonectomy for metastases. Bull Cancer 1997;84:277–281.
